Business
Notice of Interim Results
Notice of Interim Results.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 3729X Oxford BioDynamics PLC 29 April 2019 \n\n29 April 2019\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nNotice of Interim Results\n \nOxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry, expects to announce its interim results for the half-year ended 31 March 2019 on Tuesday 28 May 2019.\n \n-ENDS-\n \n \n\n\n\nOxford BioDynamics Plc.\n\n\n\n\n\n+44 (0)1865 518910\n\n\n\n\nChristian Hoyer Millar, CEO\n\n\n\n\n\n\n\n\n\n\nPaul Stockdale, CFO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nShore Capital\n\n\n\n\n\n+44 (0)20 7408 4090\n\n\n\n\nNominated Adviser and Broker \n\n\n\n\n\n\n\n\n\n\nStephane Auton\n\n\n\n\n\n\n\n\n\n\nEdward Mansfield\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting \n\n\n\n\n\n+44 (0)20 3727 1000\n\n\n\n\nFinancial Public Relations Advisor\n\n\n\n\n\n\n\n\n\n\nBrett Pollard\n\n\n\n\n\n\n\n\n\n\nNatalie Garland-Collins\n\n\n\n\n\n\n\n\n\n \n \nNotes for Editors\n \nAbout Oxford BioDynamics Plc\n \nOxford BioDynamics Plc (AIM: OBD) (\"Oxford BioDynamics\") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. \n \nThe Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. \n \nIn particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.\n \nIn April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious aw...